Breast Cancer Research and Treatment

, Volume 26, Issue 1, pp 77–88 | Cite as

Evaluation of lymphocyte immunity in breast cancer patients

  • Jonathan F. Head
  • Robert L. Elliott
  • James L. McCoy


One hundred forty-two breast cancer patients were evaluated for three functional immunologic parameters: the ability of their lymphocytes to proliferate in response to general T-(phytohemagglutinin) and B-lymphocyte (pokeweed mitogen) stimulators and their ability to proliferate in response to specific autologous tumor antigens. Tests were performed on patient blood specimens collected approximately 2 hours prior to surgery or 2–4 weeks following chemotherapy. T-lymphocyte functional competence was impaired in 83/142 (58%) of the patients, while B-lymphocyte competence was impaired in 34/142 (24%) of these patients. A total of 21/52 (40%) of the patients had lymphocyte immunity against autologous tumor antigen. There were weak associations between the ability of patients' T- and B-lymphocytes to function normally, and their ability to respond to autologous tumor-antigen. There was no relationship of age, tumor burden (clinical or pathological tumor size), extension to skin and/or muscle, or metastasis to any of the three immunological parameters. A relationship (p = 0.0463) between T-lymphocyte competence and pathological nodal status was observed; individuals that were node positive for disease, tended to have impaired T-lymphocyte function. When evaluating T- and B-lymphocyte competence and lymphocytic immunity against tumor antigen in pre- and post-chemotherapy patients, an immunologic rebound (increase in immune parameters shortly after completion of chemotherapy) was observed in some patients. These results demonstrate the utility of measuring these immune parameters in breast cancer patients, their relevance to the natural biology of the disease, and the influence that chemotherapy may have on host immune function.

Key words

breast cancer immunity T-lymphocytes B-lymphocytes tumor associated antigens pokeweed mitogen phytohemagglutinin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Watkins SM: Cancer prognosis predicted by preoperative lymphocyte responsivenessin vitro. Br J Surg 63: 433–434, 1976Google Scholar
  2. 2.
    Dean JH, Connor R, Herberman RB, Silva J, McCoy JL, Oldham RK: The relative proliferation index as a more sensitive parameter for evaluating lymphoproliferative responses of cancer patients with mitogens and alloantigens. Int J Cancer 20: 359–370, 1977Google Scholar
  3. 3.
    Humphrey LJ, Singla O, Volenec FJ: Immunological responsiveness of the breast cancer patient. Cancer 46: 893–898, 1980Google Scholar
  4. 4.
    Krown SE, Pinsky CM, Wanebo HJ, Braun DW, Wong PP, Oettgen HF: Immunologic reactivity and prognosis in breast cancer. Cancer 46: 1746–1752, 1980Google Scholar
  5. 5.
    Humphrey LJ, Humphrey MA, Singla OM, Volenec FJ: Immunologic responsiveness of patients with cancer. Ann Surg 193: 574–578, 1981Google Scholar
  6. 6.
    Cannon GB, Dean JH, Herberman RB, Keels M, Alford C: Lymphoproliferative responses to autologous tumor extracts as prognostic indicators in patients with resected breast cancer. Int J Cancer 27: 131–139, 1981Google Scholar
  7. 7.
    Burford-Mason A, Gyte GML, Watkins SM: Phytohemagglutinin responsiveness of peripheral lymphocytes and survival in patients with primary breast cancer. Breast Cancer Res Treat 13: 243–250, 1989Google Scholar
  8. 8.
    Humphrey L, Singla OM: Immune responsiveness of patients with malignant melanoma and carcinoma of the breast. Sem Surg Oncol 7: 230–238, 1991Google Scholar
  9. 9.
    Dean JH, McCoy JL, Cannon GB, Leonard CM, Perlin E, Kreutner A: Cell-mediated immune responses of breast cancer patients to autologous tumor-associated antigens. J Natl Cancer Inst 58: 549–555, 1977Google Scholar
  10. 10.
    McCoy JL, Gooding WE, Herberman RB, Weese JL, O'Brien PH, Alford CT, Mied PA, Day R: Cell-mediated immunity to tumor associated antigens as a predictor of survival in patients with breast cancer. J Clin Oncol: In PressGoogle Scholar
  11. 11.
    Nowell PC: Phytohemagglutinin: Initiator of mitosis in cultures of normal human leukocytes. Cancer Res 20: 462–466, 1990Google Scholar
  12. 12.
    Oren ME, Herberman RB: Delayed cutaneous hypersensitivity reactions to membrane extracts of human tumors. Clin Exp Immunol 9: 45–56, 1971Google Scholar
  13. 13.
    Serke S, Serke M, Brudler O: Lymphocyte activation by phytohemagglutinins and pokeweed mitogen. J Immunol Methods 99: 167–172, 1987Google Scholar
  14. 14.
    Kleightley RG, Cooper MD, Lawton AR: The T-cell dependence of B-cell differentiation induced by pokeweed mitogen. J Immunol 117: 1538–1544, 1976Google Scholar
  15. 15.
    Maguire HC, Ettore VL: Enhancement of dinitrochlorobenzene (DNCB) contact sensitivity by cyclophosphamide in the guinea pig. J Invest Dermatol 48: 39–43, 1967Google Scholar
  16. 16.
    Berd D, Mastroangelo MJ, Engstrom PF, Paul A, Maguire H: Augmentation of the human immune response by cyclophosphamide. Cancer Res 42: 4862–4866, 1982Google Scholar
  17. 17.
    Braun DP, Harris JE: Effects of combination chemotherapy on immunoregulatory cells in peripheral blood of solid tumor cancer patients: correlation with rebound overshoot immune function recovery. Clin Immunol Immunopath 20: 193–214, 1981Google Scholar
  18. 18.
    Lafreniere R, Borkenhagen K, Bryant LD, Erika N: Tumorinfiltrating lymphocytes cultured in recombinant interleukin-2: enhancement of growth, cytotoxicity, and phenotypic expression of cytotoxic T-cell antigens by cyclophosphamide given intravenously prior to tumor harvest. J Biol Response Mod 8: 238–251, 1989Google Scholar
  19. 19.
    Gazit Z, Weiss DW, Shouval D, Yechezkeli M, Schirrmacher V, Notter M, Walters J, Kedar E: Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines. Cancer Immunol Immunother 35: 135–144, 1992Google Scholar

Copyright information

© Kluwer Academic Publishers 1993

Authors and Affiliations

  • Jonathan F. Head
    • 1
  • Robert L. Elliott
    • 1
  • James L. McCoy
    • 2
  1. 1.The Elliott Mastology CenterBaton RougeUSA
  2. 2.Immuquest LaboratoriesGaithersburgUSA

Personalised recommendations